You are here: Industry Insights > Eli Lilly

News List

AbCellera, Lilly Partner to Develop Antibodies Against COVID-19 contractpharma
March 16, 2020
Will leverage AbCellera's rapid pandemic response platform and Lilly's global development, manufacturing and distribution capabilities.
FDA Grants Fast Track Designation to Jardiance for Chronic Kidney Disease americanpharmaceuticalreview
March 16, 2020
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the investigation of Jardiance® (empagliflozin) to reduce the risk of kidney disease progression ...
Eli Lilly expects no coronavirus-related drug shortages pharmaceutical-technology
March 05, 2020
Eli Lilly has announced that the company is not expecting coronavirus-related drug shortages, including all forms of insulin.
Eli Lilly's earnings, sales guidance for 2020 tops estimates firstwordpharma
December 17, 2019
Eli Lilly said Tuesday that it expects earnings per share next year in the range of $6.70 to $6.80, with overall revenue between of $23.6 billion and $24.1 billion, driven by growth from key products such as Taltz and Trulicity.
Innovent Presents Co-developed Cancer-Fighting Tyvyt(R) (Sintilimab Injection) at CIIE 2019 with Eli Lilly En-CPhI.CN
December 03, 2019
Innovent Biologics, a multinational biopharmaceutical company, and Eli Lilly and Company presented their co-developed Tyvyt® ...
U.S. biopharma CEOs look outside for growth, poll finds fiercepharma
September 26, 2019
Eli Lilly went after Loxo Oncology to beef up its presence in cancer treatment, just as Amgen is paying $13.4 billion for Celgene’s Otezla to secure a larger share of the psoriasis market alongside old TNF drug Enbrel.
Eli Lilly media chief switches up marketing mix and overhauls go-to-market model fiercepharma
September 26, 2019
By the time she took over media, the budget was 84% spent on television with the remaining amount spent mostly on print buys, along with a small share on digital for display advertising.
Lilly's first crowdsourced digital health contest seeks solutions for IBD fiercepharma
August 22, 2019
Eli Lilly is firing up its first innovation challenge for digital health, seeking technology solutions for inflammatory bowel disease. Lilly’s contest will accept entries through midnight on Sept. 30.
Eli Lilly's Taltz bests J&J rival Tremfya in head-to-head psoriasis tilt fiercepharma
August 15, 2019
It wasn’t all that long ago that Johnson & Johnson was touting head-to-head results for its psoriasis drug Tremfya against Novartis’ blockbuster Cosentyx. But now, a different rival has topped Tremfya in a showdown of its own.
Eli Lilly’s Taltz outperforms Janssen’s Tremfya in psoriasis pharmaceutical-technology
August 15, 2019
Eli Lilly has announced that its drug Taltz (ixekizumab) outperformed rival Janssen’s Tremfya in the Phase VI IXORA-R trial studying patients with moderate-to-severe plaque psoriasis.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 14 15 Next page